Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversity of Texas Southwestern Medical Center

About this trial

This is a research study to determine how COBENFY KarXT (FDA approved), a drug which has been approved for treatment of certain disorders, affects brain activity and cognitive tasks which may be regulated by the cholinergic system.

This study aims to answer: 1) how cholinergic circuitries act during task performance in humans, and 2) develop a better understanding of how cognitive control interacts with learning, memory and decision making in the setting of cholinergic manipulation.

Participants will complete a single treatment arm, regardless of which surgical procedure they are to receive. An anesthesiologist or other clinical staff will administer either the drug or the saline at a critical point which addresses the research questions, prior to patient surgery. This will be either with the drug, or the placebo pill. Half of the participants will be randomized to receive the drug, and the other half of these the placebo. Participants will be unaware whether the actual drug has been received.

Essential tremor patients who participate will complete a cognitive task during an awake surgery. Epilepsy patients who participate will have a resting state recording during the procedure from the deep cortical layers of the brain. A probe will be used during the surgery to measure the effects of this drug and other procedures of the study on the cholinergic system. This probe is the clinical probe known as the AlphaOmega, which is FDA approved for standard of care procedures.

Researchers will compare the brain activity between treatment arms to determine what brain activity changes based on the cholinergic manipulation.

Eligibility criteria

Qualifiers

Diagnosis of Essential Tremor

Recommended to undergo deep brain stimulation implantation surgery for surgical management of medication-resistant tremor based on clinical indications

Disqualifiers

Patients with recent use (within one week) of anticoagulant or antiplatelet agent

Contraindication to use of cholinergic modulation

Diagnosis of intractable epilepsy

Undergoing neuromodulation procedure that utilizes insertion of electrodes into subcortical structures, including the thalamus or hippocampus

Trial design

Treatments tested in this trial

  • Cobenfy KarXT pill (50/20 mg)
  • Placebo

Treatment groups

30 Participants
are divided into 4 treatment groups

Sponsors and collaborators

University of Texas Southwestern Medical Center

Lead sponsor

Peter O'Donnell Jr. Brain Institute

Collaborator